Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases

Recruiting now · Not applicable

Conditions studied: Glioblastoma (GBM)

In brief

This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.

Key facts

Study ID

NCT05911230

Run by

University Hospital, Basel, Switzerland

People needed

10

Starts

2022-11-24

Expected to finish

2025-11-01

Last updated by the study team

2025-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histopathologically proven glioblastoma or brain metastasis and suspected tumor progress on standard MRI after first line therapy and who are candidates for elective surgical resection.
• Able to give informed consent

You may not qualify if…

• Contraindications to MRI (e.g. claustrophobia, pacemaker or other implants without MRI-approval, pregnancy)
• Patients in a life-threatening condition
• Patients in need of emergent surgery
• Histopathological analyses of insufficient quality
• Unable to give informed consent
• Age <18 Years

Where it is running

• University Hospital Basel — Basel, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.